raw western blot data (Mendeley Ltd)
Structured Review

Raw Western Blot Data, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/raw western blot data/product/Mendeley Ltd
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Loss of Ezh2 promotes M2-like macrophage polarization in hepatocellular carcinoma"
Article Title: Loss of Ezh2 promotes M2-like macrophage polarization in hepatocellular carcinoma
Journal: iScience
doi: 10.1016/j.isci.2026.115180
Figure Legend Snippet: Effect of Hepa1-6 CM on M2 markers expression in BMDMs BMDMs were treated with Hepa1-6 CM (0, 40, and 100% (v/v) for 24 h. (A) Relative expressions of Arg1 , Mrc1 (CD206), Cd163 , and Il10 in Hepa1-6 treated-BMDM at varied concentrations were measured by RT-qPCR. (B) Representative FACS plot showing gating strategy and the percentage of CD206 + BMDMs in BMDMs that were treated with Hepa1-6 CM at varied concentrations. (C) Frequency of CD206+ cells in Hepa1-6 treated-BMDMs at varied concentrations was detected by flow cytometry. BMDMs treated with IL-4 (100 ng/mL) were used as a positive control for IL-4-induced M2 macrophages. (D) Arginase 1 expression in Hepa1-6 treated-BMDMs at varied concentrations was detected by western blot. Data expressed as mean ± S.E.M. of three biological replicates. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001. Statistical test was conducted by one-way ANOVA.
Techniques Used: Expressing, Quantitative RT-PCR, Flow Cytometry, Positive Control, Western Blot
Figure Legend Snippet: Chromatin accessibility analysis of Hepa1-6 CM-treated BMDMs WT and Ezh2 KO by ATAC-sequencing (A) Differential accessibility analysis of Hepa1-6 CM-treated BMDMs Ezh2 KO versus Hepa1-6 CM-treated BMDMs WT. (B) Differential accessibility regions showing genomic features of significant open regions in Hepa1-6 CM-treated BMDMs Ezh2 KO versus Hepa1-6 CM-treated BMDMs WT. (C) Selected significant GO term of Hepa1-6 CM-treated BMDMs Ezh2 KO significant open promoter regions. (D) Volcano plot showing RNA-seq-intersected open regions of Hepa1-6 CM-treated BMDMs Ezh2 KO versus Hepa1-6 CM-treated BMDMs WT. (E) GO analysis of RNA-seq-intersected open regions of Hepa1-6 CM-treated BMDMs Ezh2 KO. (F) Heatmap visualizing the normalized counts from RNA-seq data for genes enriched in the gene ontology (GO) term related to pyruvate metabolic processes. (G) Normalized counts of highlighted pyruvate metabolism- and TCA cycle-related genes. (H) Motif analysis of open regions enriched in pyruvate metabolic processes. (I) Open chromatin regions at the Spi1 promoter (logCPM, ATAC-seq), normalized counts of Spi1 (RNA-seq), and Spi1 (PU.1) protein expression (western blot). WT + Hepa1-6 CM = WT BMDMs treated with Hepa1-6 CM for 24 h; Ezh2 KO + Hepa1-6 CM = Ezh2 KO BMDMs treated with Hepa1-6 CM for 24 h; WT = WT BMDMs cultured in DMEM for 24 h; Ezh2 KO = Ezh2 KO BMDMs cultured in DMEM for 24 h. ATAC-seq was conducted in two biological replicates. Data expressed as mean ± S.E.M. ∗ p < 0.05 and ∗∗∗ p < 0.001 by unpaired t test.
Techniques Used: Sequencing, RNA Sequencing, Expressing, Western Blot, Cell Culture
Figure Legend Snippet: Activation of STAT3 in BMDMs by Hepa1-6 CM (A) Western blot of p-STAT3 and Arg1 in Hepa1-6 CM treated-BMDMs WT and Ezh2 KO BMDMs. This experiment was conducted independently from those shown in D. (B) Western blot of p-STAT3 in Hepa1-6 CM-treated BMDMs at selected concentrations of Tofacitinib. DMSO was used as a vehicle control by 1% v/v. WT = BMDMs WT; KO = BMDMs Ezh2 KO. Data expressed as mean ± S.E.M. of three biological replicates. ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001. Groups labeled with different letters (e.g., a, b, c) are significantly different from each other ( p < 0.05). Statistical analysis was conducted by one-way ANOVA.
Techniques Used: Activation Assay, Western Blot, Control, Labeling
